Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

  • Zabala-Letona, Amaia
  • Arruabarrena-Aristorena, Amaia|||0000-0002-1636-3944
  • Martín Martín, Natalia
  • Fernández Ruiz, Sonia
  • Sutherland, James D.|||0000-0003-3229-793X
  • Clasquin, Michelle
  • Tomás Cortázar, Julen
  • Jiménez, José
  • Torres Ramírez, Inés Ma. de
  • Quang, Phong
  • Ximénez-Embún, Pilar|||0000-0002-2582-9443
  • Bago, Ruzica
  • Ugalde Olano, Aitziber
  • Loizaga Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda, Miguel
  • Torrano, Verónica
  • Cabrera, Diana
  • van Liempd, Sebastiaan M.
  • Cendon, Ylenia
  • Castro, Elena|||0000-0002-3691-6454
  • Murray, Stuart
  • Revandkar, Ajinkya
  • Alimonti, Andrea
  • Zhang, Yinan
  • Barnett, Amelia
  • Lein, Gina
  • Pirman, David
  • Cortazar, Ana Rosa|||0000-0002-7082-5695
  • Arreal, Leire
  • Prudkin, Ludmila
  • Astobiza, Ianire|||0000-0002-7142-7066
  • Valcarcel-Jimenez, Lorea
  • Zúñiga-García, Patricia
  • Fernández Domínguez, Itziar
  • Piva, Marco
  • Caro-Maldonado, Alfredo|||0000-0002-5431-7949
  • Sánchez Mosquera, Pilar
  • Castillo Martín, Mireia
  • Serra, Violeta|||0000-0001-6620-1065
  • Beraza, Naiara
  • Gentilella, Antonio|||0000-0002-6830-2086
  • Thomas, George|||0000-0002-1236-1714
  • Azkargorta, Mikel
  • Elortza, Felix|||0000-0001-8839-5438
  • Farràs, Rosa
  • Olmos, David
  • Efeyan, Alejo
  • Anguita, Juan
  • Muñoz, Javier|||0000-0003-3288-3496
  • Falcón-Pérez, Juan M.|||0000-0003-3133-0670
  • Barrio, Rosa|||0000-0002-9663-0669
  • Macarulla Mercadé, Teresa|||0000-0002-5856-4082
  • Mato, José M.
  • Martínez Chantar, Maria L.
  • Cordon Cardo, Carlos
  • Aransay, Ana M.|||0000-0002-8271-612X
  • Marks, Kevin
  • Baselga Torres, Josep
  • Tabernero, Josep|||0000-0002-2495-8139
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Manning, Brendan D.
  • Marjon, Katya
  • Carracedo, Arkaitz|||0000-0001-5957-1260
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation,. Here we show that mTORC1 regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. Through the use of integrative metabolomics in a mouse model and human biopsies of prostate cancer, we identified alterations in tumours impacting on the production of decarboxylated S-adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This novel molecular regulation was validated in murine and human cancer specimens. AMD1 was upregulated in prostate cancer specimens with activated mTORC1. Conversely, samples from a clinical trial with the mTORC1 inhibitor everolimus exhibited a predominant decrease in AMD1 immunoreactivity that was associated to a decrease in proliferation, in line with the requirement of dcSAM production for oncogenicity. These findings provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Castroviejo-Bermejo, Marta|||0000-0002-8540-5837
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Ibrahim, Yasir Hussein
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Bonache, Sandra|||0000-0002-7395-8143
  • Morancho, Beatriz|||0000-0003-3369-8647
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Rueda, Oscar M.
  • Lai, Zhongwu|||0000-0002-1506-8222
  • Polanska, Urszula|||0000-0003-1017-594X
  • Jones, Gemma|||0000-0002-7567-681X
  • Kristel, Petra
  • de Bustos, L.
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Grueso, Judit|||0000-0003-1093-7940
  • Montalban, Gemma|||0000-0002-6958-4759
  • Caratù, Ginevra|||0000-0003-1085-8062
  • Mancuso, Francesco M.|||0000-0001-5499-6630
  • Fasani, Roberta|||0000-0003-1630-9988
  • Jiménez, Jose|||0000-0002-2576-1776
  • Howat, William J.
  • Dougherty, Brian|||0000-0002-0093-1142
  • Vivancos, Ana|||0000-0003-2888-6512
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Serres Creixams, Xavier|||0000-0001-8642-467X
  • Rubio Rodríguez, Isabel Teresa
  • Oaknin, Ana|||0000-0002-3592-7194
  • Cadogan, Elaine|||0000-0002-9757-8305
  • Barrett, J. Carl|||0000-0003-4042-9859
  • Caldas, Carlos|||0000-0003-3547-1489
  • Baselga Torres, Josep
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Jonkers, Jos|||0000-0002-9264-9792
  • Diez, Orland|||0000-0001-7339-0570
  • O'Connor, Mark J.|||0000-0003-1823-625X
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Serra, Violeta|||0000-0001-6620-1065
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). Their efficacy in germline BRCA1/2 (gBRCA1/2)-mutated metastatic breast cancers has been recently confirmed in clinical trials. Numerous mechanisms of PARPi resistance have been described, whose clinical relevance in gBRCA-mutated breast cancer is unknown. This highlights the need to identify functional biomarkers to better predict PARPi sensitivity. We investigated the in vivo mechanisms of PARPi resistance in gBRCA1 patient-derived tumor xenografts (PDXs) exhibiting differential response to PARPi. Analysis included exome sequencing and immunostaining of DNA damage response proteins to functionally evaluate HRR. Findings were validated in a retrospective sample set from gBRCA1/2-cancer patients treated with PARPi. RAD51 nuclear foci, a surrogate marker of HRR functionality, were the only common feature in PDX and patient samples with primary or acquired PARPi resistance. Consistently, low RAD51 was associated with objective response to PARPi. Evaluation of the RAD51 biomarker in untreated tumors was feasible due to endogenous DNA damage. In PARPi-resistant gBRCA1 PDXs, genetic analysis found no in-frame secondary mutations, but BRCA1 hypomorphic proteins in 60% of the models, TP53BP1 -loss in 20% and RAD51 -amplification in one sample, none mutually exclusive. Conversely, one of three PARPi-resistant gBRCA2 tumors displayed BRCA2 restoration by exome sequencing. In PDXs, PARPi resistance could be reverted upon combination of a PARPi with an ataxia-telangiectasia mutated (ATM) inhibitor. Detection of RAD51 foci in gBRCA tumors correlates with PARPi resistance regardless of the underlying mechanism restoring HRR function. This is a promising biomarker to be used in the clinic to better select patients for PARPi therapy. Our study also supports the clinical development of PARPi combinations such as those with ATM inhibitors.